Current Oncology, Volume 20, Issue 2

Purpose: The objective of the present study was to analyze, with relatively high sensitivity and specificity, uptake properties of [11C]-choline in prostate cancer patients by means of positron-emission tomography (pet)/computed tomography (ct) imagi...

Background: The burden of axillary disease in patients with locally advanced breast cancer (labc) after neoadjuvant therapy (nat) has not been extensively described in a large modern cohort. Here, we describe the extent of nodal metastases after nat...

The 2012 Cancer System Performance Report is the 4th annual report on the Canadian cancer control system produced by the System Performance initiative at the Canadian Partnership Against Cancer, in collaboration with its provincial and national partn...

JSH: In July 2011, the pan-Canadian Oncology Drug Review [pcodr (http://www.pcodr.ca/)] began accepting submissions by pharmaceutical manufacturers and clinician-based tumour groups to have cancer drugs reimbursed by provincial payers in Canada. Does...

The practice of medicine and the experience of being a patient or a caregiver both provide rich thematic material for the creation of narratives—or, to put it more plainly, story-telling. [...]

Steven Narod’s latest Countercurrents contribution to Current Oncology discusses a new breast and ovarian cancer susceptibility gene known as PPM1D. [...]

A fascinating article, recently published in Nature and titled “Mosaic PPM1D Mutations Are Associated with Predisposition to Breast and Ovarian Cancer” by Nazneen Rahman and her colleagues, is a rare example of a discovery that causes a re-evaluation...

Background: Neurocognitive deficits from brain tumours may impair the ability to safely operate a motor vehicle. Although certain jurisdictions in Canada legally require that physicians report patients who are unfit to drive, criteria for determining...

Background: Altered formulations of taxanes may lack cross-resistance with standardly used solvent-based taxanes. The primary objective of the present study was to assess the clinical benefit of nanoparticle albumin-bound (nab)–paclitaxel in women wi...

Background: Panitumumab is a fully human monoclonal antibody, directed against the epidermal growth factor receptor, that was shown to be effective in third-line metastatic colorectal cancer. We performed a retrospective analysis of patients with che...